{"id":"NCT02008227","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy","officialTitle":"A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Failure With Platinum Containing Chemotherapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-03-11","primaryCompletion":"2016-07-07","completion":"2019-01-09","firstPosted":"2013-12-11","resultsPosted":"2017-07-02","lastUpdate":"2019-12-20"},"enrollment":1225,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Non-Squamous Non-Small Cell Lung Cancer"],"interventions":[{"type":"DRUG","name":"Atezolizumab","otherNames":["Tecentriq"]},{"type":"DRUG","name":"Docetaxel","otherNames":[]}],"arms":[{"label":"Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody","type":"EXPERIMENTAL"},{"label":"Docetaxel","type":"ACTIVE_COMPARATOR"}],"summary":"This global, multicenter, open-label, randomized, controlled study evaluated the efficacy and safety of atezolizumab (an anti-programmed death-ligand 1 \\[anti-PD-L1\\] antibody)compared with docetaxel in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure with platinum-containing chemotherapy. Participants were randomized 1:1 to receive either docetaxel or atezolizumab. Treatment may continue as long as participants experienced clinical benefit as assessed by the investigator, i.e., in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression.","primaryOutcome":{"measure":"Percentage of Participants Who Died: PP-ITT","timeFrame":"Baseline until death due to any cause (up to approximately 2.25 years)","effectByArm":[{"arm":"Docetaxel","deltaMin":70.1,"sd":null},{"arm":"Atezolizumab","deltaMin":63.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":7},"locations":{"siteCount":208,"countries":["United States","Argentina","Austria","Brazil","Canada","Chile","Finland","France","Germany","Greece","Guatemala","Hungary","Italy","Japan","Netherlands","New Zealand","Norway","Panama","Poland","Portugal","Russia","Serbia","South Korea","Spain","Sweden","Switzerland","Taiwan","Thailand","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["37696652","37004206","36428744","35727053","34226144","33737340","33241650","32115349","31542806","30642441","30017645","29525239","27979383"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":180,"n":578},"commonTop":["Fatigue","Decreased appetite","Cough","Nausea","Diarrhoea"]}}